



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
12.04.2023 Bulletin 2023/15

(45) Date of publication and mention
of the grant of the patent:
08.03.2023 Bulletin 2023/10

(21) Application number: **18792709.0**

(22) Date of filing: **01.10.2018**

(51) International Patent Classification (IPC):
C07C 309/82 ^(2006.01) **C07D 417/12** ^(2006.01)
A61P 31/04 ^(2006.01) **A61K 31/506** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07D 417/12; A61K 31/427; A61P 31/04;
C07C 309/82; Y02A 50/30

(86) International application number:
PCT/US2018/053778

(87) International publication number:
WO 2019/070595 (11.04.2019 Gazette 2019/15)

(54) **AZTREONAM DERIVATIVES AND USES THEREOF**

AZTREONAMDERIVATE UND VERWENDUNGEN DAVON

DÉRIVÉS D'AZTRÉONAM ET UTILISATIONS ASSOCIÉES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **02.10.2017 US 201762566909 P**

(43) Date of publication of application:
08.07.2020 Bulletin 2020/28

(73) Proprietor: **Arixa Pharmaceuticals, Inc.**
New York, NY 10001-2192 (US)

(72) Inventors:
• **GORDON, Eric, M.**
Palo Alto, CA 94301 (US)
• **DUNCTON, Matthew, A.j.**
Palo Alto, CA 94301 (US)
• **FREUND, John**
Palo Alto, CA 94301 (US)

(74) Representative: **Pfizer**
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 (FR)

(56) References cited:
• **MAREIKE KLINGER-STROBEL ET AL: "Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis - where do we stand?", EXPERT OPINION ON DRUG DELIVERY, vol. 12, no. 8, 2 February 2015 (2015-02-02), pages 1351-1374, XP055524515, GB ISSN: 1742-5247, DOI: 10.1517/17425247.2015.1007949**
• **DAVID HUTCHINSON ET AL: "Inhaled aztreonam lysine: an evidence-based review", EXPERT OPINION ON PHARMACOTHERAPY, vol. 14, no. 15, 31 August 2013 (2013-08-31), pages 2115-2124, XP055524539, LONDON, UK ISSN: 1465-6566, DOI: 10.1517/14656566.2013.831070**
• **Aukje C. Bos ET AL: "Patient-Specific Modeling of Regional Antibiotic Concentration Levels in Airways of Patients with Cystic Fibrosis: Are We Dosing High Enough?", PLOS ONE, vol. 10, no. 3, 3 March 2015 (2015-03-03), page e0118454, XP055524514, DOI: 10.1371/journal.pone.0118454**
• **I.M. Balfour-Lynn: "At last, Burkholderia spp. is one of the inclusion criteria ? A negative (but published) randomised controlled trial", Journal of Cystic Fibrosis, vol. 13, no. 3, 1 May 2014 (2014-05-01), pages 241-242, XP055524541, NL ISSN: 1569-1993, DOI: 10.1016/j.jcf.2014.01.003**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- ERIC M. GORDON ET AL: "Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2", ACS MEDICINAL CHEMISTRY LETTERS, vol. 11, 8 January 2020 (2020-01-08), pages 162-165,

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification